

1 **Title:** Therapeutic Prospects for Th-17 Cell Immune Storm Syndrome and Neurological  
2 Symptoms in COVID-19: Thiamine Efficacy and Safety, In-vitro Evidence and Pharmacokinetic  
3 Profile  
4

5 **Author List:** Vatsalya Vatsalya, MD, MS, PgD, MSc<sup>1,2\*</sup>, Fengyuan Li, PhD<sup>1,3</sup>, Jane Frimodig,  
6 PhD<sup>1,2</sup>, Khushboo S. Gala, MD<sup>1</sup>, Shweta Srivastava, PhD<sup>1,4</sup>, Maiying Kong, PhD<sup>2,5</sup>, Vijay A  
7 Ramchandani, PhD<sup>6</sup>, Wenke Feng, PhD<sup>1,3,7,10</sup>, Xiang Zhang, PhD<sup>3,7,8,9,10</sup>, Craig J McClain,  
8 MD<sup>1,2,3,7,10</sup>  
9

10 **Affiliations:**

11 <sup>1</sup>Department of Medicine, University of Louisville, Louisville, KY USA

12 <sup>2</sup>Robley Rex VA Medical Center, Louisville, KY USA

13 <sup>3</sup>University of Louisville Alcohol Research Center, Louisville, KY USA

14 <sup>4</sup>Envirome Institute, University of Louisville, Louisville, KY USA

15 <sup>5</sup>Department of Bioinformatics and Biostatistics, University of Louisville, Louisville, KY USA

16 <sup>6</sup>National Institute on Alcohol Abuse and Alcoholism, NIH, Bethesda, MD USA

17 <sup>7</sup>Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY USA

18 <sup>8</sup>Department of Chemistry, University of Louisville, Louisville, KY USA

19 <sup>9</sup>Center for Regulatory and Environmental Analytical Metabolomics, University of Louisville,  
20 Louisville, KY USA

21 <sup>10</sup>University of Louisville Hepatobiology & Toxicology COBRE, Louisville, KY USA  
22

23 **\*Corresponding Author:**

24 Vatsalya Vatsalya, MD, MS, PgD, MSc

25 Department of Medicine

26 University of Louisville School of Medicine

27 505 S. Hancock St., CTR Room 514A

28 Louisville KY 40202

29 Landline: 502-852-8928, Fax: 502-852-8927

30 Cell: 502-488-0446; Email: [v0vats01@louisville.edu](mailto:v0vats01@louisville.edu)  
31

32 **Running Head:** Thiamine Treatment for COVID-19: Th17 Immune Storm and Neurological  
33 Symptoms.  
34

35 **Author contribution:** VV is the project PI and designed the study. VV and JF participated in the  
36 clinical sampling and clinical data analyses. FL performed *in vitro*, and JF performed plasma  
37 testing. FL, JF, and VV participated in the overall laboratory analyses. MK and VV developed the  
38 dosing range. VV, CJM and VAR developed the pharmacokinetic profile. VV, FL, SS, and JF  
39 interpreted the results. VV, FL, JF, SS, and KSG wrote the manuscript. CJM, MK, WF, XZ, and VAR  
40 critically reviewed the manuscript and contributed scientifically. All authors have approved the  
41 submission version of this manuscript.  
42

43 **Conflicts of Interest:** All authors declare no conflict of interests.  
44

45 **Proprietorship:** This article is a work of the University of Louisville Alcohol Research Center and  
46 National Institutes of Health. This manuscript is in the public domain in the USA. Email address  
47 for the readers to contact the author to obtain the data: [v0vats01@louisville.edu](mailto:v0vats01@louisville.edu).  
48

49 **Project/Grant Support:** Study was supported by NIH: NIH-OD-OHSRP-12176 (VV),  
50 R15CA170091-01A1 (MK), ZIA AA000466 (VAR), R01AA023190 (WF), P50AA024337-8301 and  
51 P20GM113226-6169 (XZ), and P50AA024337, P20GM113226, U01AA026936, U01AA0279880,  
52 R01AA023681 (CJM). The content is solely the responsibility of the authors and does not  
53 necessarily represent the official views of the National Institutes of Health.  
54

55 **Acknowledgments:** We thank research/clinical staff of the University of Louisville for their  
56 support. We thank Ms. Marion McClain for editing this manuscript.  
57

58 **Ethics approval and consent to participate:** Study was approved by the sites' Institutional  
59 Review Boards (Ethics committees). All patients included in this study consented to participate  
60 before the beginning of the study.  
61

62 **Availability of data and materials:** The datasets analyzed during the current study are available  
63 from the corresponding author by request.  
64

65 **Disclosure:** This article is not published nor is under consideration for publication elsewhere at  
66 the time of submission.  
67

68 **Abbreviations:** COVID-19: Coronavirus Disease-19, IL-17: Interleukin 17, IL-22: Interleukin 22,  
69 Disease Controls: (DC), HV: Healthy Volunteers.  
70

71 **Trial registration:** ClinicalTrials.gov identifier - NCT# 01809132 and 00106106.  
72

73 **Reprint requests:** Vatsalya Vatsalya MD, PgD, MSc, MS, Department of Medicine, University of  
74 Louisville School of Medicine, 505 S. Hancock St., CTR Room 514A, Louisville KY 40202 USA. Tel.:  
75 502-852-8928. Fax: 502-852-8927. E-mail: [v0vats01@louisville.edu](mailto:v0vats01@louisville.edu).  
76

77 **Manuscript metadata:**

78 Word Count in manuscript draft: 3383 manuscript words.

79 Tables and Figures: 1 Table, 4 Figures, and 2 Suppl. Tables.

80 Number of References: 110.  
81

82

83

84

85 **Abstract**

86 Introduction

87 Emerging infectious diseases, especially the coronavirus disease identified in 2019  
88 (COVID-19), can be complicated by a severe exacerbation in the Th17 cell-mediated IL-17  
89 proinflammatory immune storm. This enhanced immune response plays a major role in  
90 mortality and morbidity, including neurological symptoms. We hypothesized that countering  
91 the cytokine storm with thiamine may have therapeutic efficacy in lowering the Th17 cell  
92 proinflammatory response. We used an *in vitro* study and corroborated those results in disease  
93 controls (DC). We developed an effective dose range and model for key pharmacokinetic  
94 measures with the potential of targeting the cytokine storm and neurological symptoms of  
95 COVID-19.

96 Study Participants and Methods

97 We investigated the effect of a three-week 200 mg dose of thiamine in lowering the  
98 Th17 response in sixteen DC (proinflammatory origin due to heavy alcohol drinking) patients;  
99 and eight healthy control/volunteers (HV) as a pilot clinical-translational investigation. To  
100 further investigate, we performed an *in vitro* study evaluating the effectiveness of thiamine  
101 treatment in lowering the Th17 proinflammatory response in a mouse macrophage cell line  
102 (RAW264.7) treated with ethanol. In this *in vitro* study, 100 mg/day equivalent (0.01 µg/ml)  
103 thiamine was used. Based on recent publications, we compared the results of the IL-17  
104 response from our clinical and *in vitro* study to those found in other proinflammatory disease  
105 conditions (metabolic conditions, septic shock, viral infections and COVID-19), including  
106 symptoms, and dose ranges of effective and safe administration of thiamine. We developed a

107 dose range and pharmacokinetic profile for thiamine as a novel intervention strategy in COVID-  
108 19 to alleviate the effects of the cytokine storm and neurological symptoms.

### 109 Results

110 The DC group showed significantly elevated proinflammatory cytokines compared to  
111 HV. Three-week of 200 mg daily thiamine treatment significantly lowered the baseline IL-17  
112 levels while increased IL-22 levels (anti-inflammatory response). This was validated by an *in*  
113 *vitro* macrophage response using a lower thiamine dose equivalent (100 mg), which resulted in  
114 attenuation of IL-17 and elevation of IL-22 at the mRNA level compared to the ethanol-only  
115 treated group. In humans, a range of 79-474 mg daily of thiamine was estimated to be effective  
116 and safe as an intervention for the COVID-19 cytokine storm. A literature review showed that  
117 several neurological symptoms of COVID-19 (which exist in 45.5% of the severe cases) occur in  
118 other viral infections and neuroinflammatory states that may also respond to thiamine  
119 treatment.

### 120 Discussion

121 The Th17 mediated IL-17 proinflammatory response can potentially be attenuated by  
122 thiamine. Thiamine, a very safe drug even at very high doses, could be repurposed for treating  
123 the cytokine/immune storm of COVID-19 and the subsequent neurological symptoms observed  
124 in COVID-19 patients. Further studies using thiamine as an interventional/prevention strategy in  
125 severe COVID-19 patients could identify its precise anti-inflammatory role.

126

127 **Key words:** COVID-19, IL-17, IL-22, Cytokine storm, Pandemic

128

## 129 **Introduction**

130           Viral diseases and wide-spread outbreaks have adverse health-related consequences  
131 worldwide. Emerging infectious diseases (EID) include viral pathogens that have shown higher  
132 incidence of human infection in the past several decades and raise concerns regarding  
133 increased ongoing/future prevalence <sup>1</sup>. Coronavirus is recognized as an EID that has become a  
134 challenging and aggressive infection with high morbidity and mortality in humans <sup>2</sup>. SARS-CoV-2  
135 (severe acute respiratory syndrome coronavirus 2; causes coronavirus disease [COVID-19]) was  
136 identified in 2019, has become a pandemic, and is a priority healthcare concern in the year  
137 2020 <sup>3</sup>.

138           In viral infections, tissue inflammation is driven by multiple proinflammatory and  
139 immunoregulatory signals <sup>4,5</sup>. The pathological progression of COVID-19 has multiple clinical  
140 stages and may present with the cytokine storm syndrome <sup>6</sup> and immunosuppression <sup>7</sup>.  
141 Interleukin-17 (IL-17) is a cytokine <sup>8</sup> that is often involved in a proinflammatory response in the  
142 cytokine storm of viral infections <sup>9-11</sup>. It can also promote respiratory viral infections <sup>12</sup>, tissue  
143 pathology <sup>13-15</sup>, and neurological manifestations <sup>16</sup>. Th17 cells also produce Interleukin-22 (IL-  
144 22), which plays a protective/anti-inflammatory role, and it is dysregulated in several  
145 proinflammatory conditions <sup>17</sup>. Thus, a therapy that could alleviate the Th17 mediated pro-  
146 inflammatory response <sup>18</sup> might be effective in attenuating the cytokine storm observed in  
147 COVID-19 patients.

148           Thiamine, a vitamin and dietary supplement, <sup>19</sup> has anti-oxidant properties <sup>19,20</sup>. High  
149 levels of cytokines (for example, IL-1 $\beta$  and IL-6) may occur in thiamine deficient subjects and  
150 can be associated with oxidative stress and inflammation <sup>21,22</sup>. Importantly, thiamine

151 administration could inhibit production of these cytokines, increase anti-inflammatory activity  
152 <sup>23,24</sup>, and potentially alleviate neuroinflammatory symptoms of viral origin <sup>25,26</sup>.

153 We tested the efficacy of a three-week thiamine treatment in modulating the Th17  
154 proinflammatory response in a human disease control model of conditions associated with  
155 inflammation. To validate the effectiveness of thiamine in treating the proinflammatory  
156 response from the human study, we conducted an *in vitro* experiment to test the effects of  
157 thiamine treatment in alleviating ethanol mediated immune dysregulation in a mouse  
158 macrophage cell line, RAW264.7. We investigated the Th17 cells proinflammatory cytokine  
159 response (namely IL-17) in both healthy controls and individuals with high inflammatory  
160 response. This was done to estimate the effects of various doses of thiamine that have shown  
161 efficacy in alleviating the Th17 associated cytokine response. We assessed the  
162 pharmacokinetics of the oral thiamine dosing. Lastly, we also examined the neurological  
163 symptoms of COVID-19 that could possibly be treated with thiamine.

164

## 165 **Study Participants and Methods**

### 166 *Study Participants*

167 This investigation was approved under two large clinical investigations that were  
168 conducted at the University of Louisville (NCT#01809132, HV cohort), and the National Institute  
169 on Alcohol Abuse and Alcoholism (NIAAA) (NCT#00106106, DC cohort) at the National Institutes  
170 of Health (NIH), Bethesda MD. The studies were approved by the NIH Institutional Review  
171 Board (IRB) committee and the UofL IRB (IRB # 12.0427). All DC (disease controls as termed in  
172 this study, who were alcohol use disorder [AUD]) patients received acamprosate (or placebo) as

173 part of a larger addiction intervention investigation. All of these patients also received thiamine  
174 as part of the medical management, which is the primary aim of this study. Sixteen age- and  
175 sex- matched male and female alcohol use disorder (AUD) patients (Termed as disease controls  
176 [DC] in this investigation) between 21-65 yrs. of age with both present and past heavy drinking  
177 profile participated as the DC, who were diagnosed with AUD based on DSM-IV TR criteria.  
178 They received daily doses of open label thiamine (100 mg twice daily = 200 mg per day)<sup>27</sup> for 3-  
179 weeks after completion of the consenting process. DC patients also received standard of care  
180 inpatient medical management, including counseling. Detailed information on subject  
181 recruitment and management can be obtained from several of our previous publications<sup>28-31</sup>.  
182 We also included eight healthy controls in this study for comparison with DC. Demographic data  
183 were collected from all the participants. Baseline (HV and DC) and post-treatment (DC only)  
184 blood samples (after the completion of 3-weeks of thiamine dosing) were collected, processed  
185 (for plasma extraction) and frozen at -80°C. They were subsequently thawed and assayed.

#### 186 *Laboratory Assays and Therapeutic Model on Th17 Inflammation Axis*

##### 187 (1) Cytokine assays

188 Plasma levels of proinflammatory cytokines, IL-1 $\beta$ , IL-6, and IL-10 were obtained by  
189 multianalyte chemiluminescent detection using Multiplex kits (Millipore, Billerica, MA) on the  
190 Luminex platform (Luminex, Austin, TX), according to manufacturers' instructions.

##### 191 (2) Analysis of IL-17 and IL-22 in a set of AUD patients for designing proof-of-concept 192 experimental model

193 We performed analyses for IL-17 and IL-22 on human plasma samples to estimate the  
194 Th17 inflammatory response, with the goal of developing an *in vitro* mechanistic experimental

195 model to test the efficacy of thiamine. The plasma levels of IL-17 and IL-22 in eight healthy  
196 volunteers were also included in this study for comparison. IL-17 and IL-22 were detected in  
197 plasma using Human IL-17A (now called IL-17) High Sensitivity ELISA Kits (BMS2017HS,  
198 Invitrogen) and Human IL-22 ELISA Kits (BMS2047, Invitrogen) per the manufacturer's  
199 instructions. Results were read on a Spectra Max Plus 384 plate reader and modeled using their  
200 SoftMax Pro software (Molecular Devices, San Jose, CA).

### 201 (3) Cell culture

202 RAW 264.7 cells (mouse macrophage cell line) were cultured in Dulbecco's modified  
203 Eagle's medium (DMEM, Invitrogen), supplemented with 10% fetal bovine serum (FBS) and 1%  
204 penicillin/streptomycin. Cells were seeded in a 24-well culture plate and maintained at 37 °C in  
205 a 5% CO<sub>2</sub> incubator for 3 days. The 0.02 µg/mL treatment dose was equivalent to the 200  
206 mg/day thiamine dose (approximate blood AUC = 204 nmol/L<sup>32</sup>) given to the patients. Cells  
207 were then treated with thiamine (Vit B1 [V<sub>B1</sub>]) as shown in the Figure 2) at a concentration of  
208 (0.01 µg/mL) for 2 hours (in a preventive paradigm), followed by 80 mM ethanol treatment for  
209 22 hours, for a total of 24 hours of treatment to determine the minimum effective level of  
210 thiamine to reduce the Th17 response. Cells were then washed with PBS and collected with  
211 Trizol reagent for the isolation of RNA. RNA samples were reverse transcribed to cDNA and  
212 used for qRT PCR analysis of cytokine expression (IL-17, IL-22). Cell viability was not affected by  
213 thiamine or EtOH treatment at the doses used in the experiments.

### 214 (4) RNA isolation and real-time RT-PCR

215 Total RNA was extracted from the cells using Trizol reagent (500 µl/well) according to  
216 manufacturer's instruction (Life Technologies, Carlsbad, CA) and reverse-transcribed using

217 cDNA Supermix (QuantaBio, Beverly, MA). Quantitative real-time PCR was performed on an ABI  
218 7500 real-time PCR thermocycler and SYBR green PCR Master Mix (Applied Biosystems, Foster  
219 City, CA) was used for quantitative real-time PCR analysis. The relative quantities of target  
220 transcripts were calculated from duplicate samples after normalization of the data against the  
221 housekeeping gene, mouse 18S. Relative mRNA expression was calculated using comparative Ct  
222 method. The following primer pairs were used:

Gene name	Forward sequence 5'→3'	Reverse sequence 5'→3'
ms <i>IL-17</i>	ATCCCTCAAAGCTCAGCGTGTC	GGGTCTTCATTGCGGTGGAGAG
ms <i>IL-22</i>	GTCAACCGCACCTTTATGCT	CATGTAGGGCTGGAACCTGT
ms <i>18S</i>	GTAACCCGTTGAACCCATT	CCATCCAATCGGTAGTAGCG

223

#### 224 *Development of the Pharmacokinetic Model for Dose Titration of Thiamine*

225 We used dosing guidelines for thiamine as mentioned at the Medline Plus  
226 (<https://medlineplus.gov/druginfo/natural/965.html#Safety>, last reviewed as of August 5,  
227 2020), and from peer reviewed publications from PubMed (<https://pubmed.ncbi.nlm.nih.gov/>;  
228 [searched and collected until August 5, 2020]). We used available dosing guidelines from  
229 Medline Plus for healthy individuals both for dietary supplementation and vitamin deficiency  
230 status. We also reviewed and incorporated thiamine dose levels (lower and higher range) from  
231 other disease conditions; namely metabolic conditions<sup>33,34</sup>, septic shock<sup>35,36</sup>, viral diseases<sup>37-39</sup>  
232 and Leigh's disease<sup>40</sup> ([Medline Plus: Thiamine](#)). We also included the recorded thiamine dose  
233 levels from the DC group (AUD with Wernicke Korsakoff Syndrome, WKS<sup>41</sup>; from our clinical  
234 study) as one of the pro-inflammatory conditions.

235 We compared the reference range of levels of the Th17 cytokine (IL-17) response in  
236 disease/health conditions in humans as published in the recent findings concerning COVID-19's  
237 cytokine storm data<sup>42-44</sup>. A Th17 proinflammatory response for the potential range of IL-17  
238 levels was also developed for healthy volunteers (HV, from our study cohort), metabolic  
239 conditions<sup>45,46</sup>, DC (or alcohol use disorder patients from our study cohort), septic shock<sup>47,48</sup>,  
240 and viral infections<sup>12,49</sup>. IL-17 data on severe COVID-19 patients (as mentioned above) were  
241 collected from the recently peer-reviewed published articles found in PubMed (searched until  
242 August 5, 2020). Doses administered to our DC study cohort, and data from healthy individuals  
243 (HV) were also used in the development of the dose profile. All these data were incorporated in  
244 the predictive regression model for identifying a tentative effective dose range of thiamine  
245 (Figure 3).

246 The pharmacokinetic response of thiamine was calculated at both the low and high ends  
247 of the dose range described above. The area under the curve and maximum concentration  
248 ( $C_{max}$ ) were established for both blood and plasma for a 10-hour trajectory (Figure 4) using the  
249 indices of thiamine's *in vivo* blood pharmacokinetics<sup>32</sup>. For the derived 79 mg thiamine dosing  
250 (low end), the slopes used to identify AUC in blood were 2.14, and 1.76 in plasma. For the 474  
251 mg thiamine dosing (upper end), the slope used to derive AUC in blood was 1.02, while in  
252 plasma it was 1.09. Similarly, for the 79 mg thiamine dosing, the slope used to derive  $C_{max}$  in  
253 blood was 0.40, and in plasma it was 0.39. For the 474 mg thiamine dose, the slope used to  
254 derive AUC in blood was 0.14, and in plasma it was 0.18.

255 *Statistical Analysis*

256 Data are expressed as Mean  $\pm$  standard deviation (M $\pm$ SD) in Table 1 as well as in Figures  
257 1 and 2. Two-sided Student's t-test was used to examine the difference between disease  
258 controls and healthy volunteers at baseline (see Suppl. Table 1 and Fig. 1), and two-sided  
259 Student's paired t-test was used to examine the changes at baseline versus 3 weeks for disease  
260 controls (Figure 1).

261 *Post-hoc* one-sided t-tests were performed for the IL-17 and IL-22 mRNA expression  
262 analyses for the RAW 264.7 cells testing (Figure 2). A pharmacokinetic model for anticipated  
263 therapeutic dosing range of thiamine based on IL-17 ranges in different inflammatory  
264 conditions was constructed using predictive regression computation (Figure 3). Factorial  
265 between-group ANOVA was used to evaluate demographic and cytokine profiles (Table 1).  
266 Statistical significance was established at  $p < 0.05$ . SPSS 26.0 (IBM Chicago, IL) and Microsoft  
267 Excel 365 (MS Corp, Redmond WA), statistical software R (<https://www.r-project.org/>), and  
268 Prism GraphPad (GraphPad Software, San Diego CA) were used for statistical analysis, data  
269 computation, and plotting the figures.

#### 270 *Neurological Assessments*

271 We conducted a review on the neurological presentation in COVID-19 and other  
272 relevant viral occurrences of encephalitis (Table 1). We identified and tabulated the  
273 neurological symptoms of COVID-19 and viral encephalitis from the recently published findings.  
274 We also described the neurological symptoms, that are generally treated effectively with  
275 thiamine (Table 1). We used PubMed and Medline Plus for disease references (searched until  
276 August 5, 2020).

277

278 **Results**

279 *Demographics and Candidate Proinflammatory Cytokine Profile*

280 DC group individuals in this study had significantly higher age than the healthy controls  
281 (HV) (Suppl Table 1). However, there was no significant difference in the mean BMIs between  
282 the two groups, and the sex-distribution was also similar between the two groups. Both IL-6 (~6  
283 fold) and IL-1 $\beta$  (~3 fold) cytokines were significantly higher in the DC group (AUD patients)  
284 compared to the healthy controls/volunteers (HV) group. IL-10 was also numerically higher in  
285 the DC group.

286

287 *Clinical Findings on the Immune Response of Th17 derived IL-17 and IL-22 Axis Response, and*  
288 *Thiamine Efficacy and Safety*

289 To develop a model for thiamine effects on inflammation, we assessed IL-17 and IL-22  
290 cytokine expression (showing proinflammatory and anti-inflammatory effects, respectively).  
291 Both cytokines are produced by the Th17 cells<sup>50</sup>. IL-17 concentrations were below the level of  
292 detection in the HV group, but were elevated in the DC group. An approximate four-fold  
293 decrease was observed in the IL-17 concentration levels (0.09 pg/mL to 0.023 pg/mL) with a  
294 treatment dose of 200 mg thiamine daily (Estimated AUC = 204 nmol/L x hour approximately in  
295 the 10-hr. window) by the end of week 3. IL-22 was significantly decreased in DC group  
296 compared to healthy volunteers and thiamine therapy did not significantly improve levels in  
297 treated DC group individuals. No patients reported any kind of drug related adverse events;  
298 therefore, the safety profile of thiamine administration was excellent at 200 mg daily in this  
299 small pilot group.

300

301 *Experimental Model for Treatment Efficacy of Thiamine on IL-17 and IL-22 Activity*

302           Using these clinical findings of the treatment efficacy of thiamine, we designed an *in*  
303 *vitro* experiment using mouse macrophage RAW264.7 cells to validate the effects of thiamine  
304 on alcohol-induced IL-17 and IL-22 expression. The results showed that a low dose of thiamine  
305 (V<sub>B1</sub>) decreased IL-17 expression in the absence (by 20% approximately) and/or presence of  
306 alcohol treatment (by 25% roughly) (Figure 2a). Importantly, IL-22 expression was upregulated  
307 by thiamine in both the control and ethanol-treated cells. This response in IL-22 expression was  
308 moderately reduced by alcohol but rescued by the thiamine (V<sub>B1</sub>) treatment (Figure 2b). Half of  
309 the treatment dose (0.02 µg/mL) that was found to be effective in humans was beneficial as a  
310 preventative dose (0.01 µg/mL) of thiamine in this *in vitro* model.

311

312 *IL-17 Dependent Dose and Pharmacokinetic Model of Thiamine*

313           An IL-17 response dependent dose and pharmacokinetic model of thiamine  
314 administration was developed, based on responses from the pro-inflammatory disease cohorts  
315 and the corresponding thiamine dosing (controlled for by the corresponding values in healthy  
316 volunteers, as a point of reference). This model supported a tentative range of thiamine dosing  
317 for COVID-19 (Figures 3A and 3B), since the IL-17 levels are much higher in COVID-19 than in  
318 the reports from many other proinflammatory disease conditions. Using regression analysis, a  
319 range of 79 mg/day (lower end of dose range) - 474 mg/day (higher end of dose range) for  
320 thiamine administration was found to correspond to a range of 15-40 ng/mL level of IL-17 used  
321 *in vitro*.

322           The pharmacokinetic parameters were: Area Under the Curve (AUC), and Maximum (or  
323 peak) Concentration of a drug ( $C_{max}$ ). These gave a very close estimation of the specific oral  
324 thiamine dose (Figure 4). As expected, plasma values were higher for both AUC and  $C_{max}$  at  
325 higher doses and were lower at lower doses (Suppl Table 2).

326

327 *Assessment of Neurological Presentation of COVID-19, Viral Encephalitis and Therapeutic*  
328 *Efficacy of Thiamine Administration*

329           We tabulated the neurological symptoms from the recently published findings on  
330 COVID-19 (Table 1). Severely ill COVID-19 patients presented with various neurologic symptoms  
331 that could be grouped together as: acute cerebrovascular disease; altered mental status; and  
332 musculoskeletal symptoms<sup>51</sup>. We also included the neurological presentation commonly  
333 observed in viral encephalitis of non-COVID-19 origin, grouped corresponding to the  
334 presentation of the symptoms of COVID-19.

335           Lastly, we also tabulated the neurological symptoms that are commonly treated with  
336 thiamine. Several neurological symptoms of COVID-19 and viral encephalitis corresponded well  
337 with the neurological spectrum that is known to be managed effectively with thiamine.

338

339 **Discussion**

340           We evaluated individuals with significantly altered IL-17 and IL-22 responses associated  
341 with Th17 cells and found a significant role for a 3-week 200 mg/daily thiamine treatment  
342 regimen in improving the Th17 response in the AUD disease control patient cohort whose  
343 members exhibited a high pro-inflammatory status at baseline. SARS CoV-2 viral challenge

344 causes induction of IL-6 leading to altered Th17 responses<sup>52</sup>. IL-17 synthesized by Th17 cells  
345 can markedly stimulate neutrophil chemotaxis and may lead to a skewed Th2 immune response  
346<sup>53,54</sup>. Results from our AUD control group show the increases in candidate proinflammatory (IL-  
347 1 $\beta$  and IL-17), and anti-inflammatory (IL-6, IL-10 and IL-22) cytokines. Changes in IL-17 and IL-22  
348 with alcohol abuse (pro-inflammatory), and thiamine as an anti-inflammatory therapy in our  
349 experiment provided potential proof of concept. IL-1 $\beta$  is a key cytokine initiating Th17 cells to  
350 synthesize IL-17<sup>55</sup>, whereas IL-10 suppresses Th17 proinflammatory cytokine production<sup>56</sup>.  
351 High IL-6 levels also are associated with Th17 cell proinflammatory activity<sup>52</sup>. Thus, under  
352 inflammatory conditions, there is a complex interaction of proinflammatory/anti-inflammatory  
353 responses from Th17 cells. An intervention or prevention that could attenuate the Th17  
354 proinflammatory activity could help ameliorate the consequences of a cytokine storm.

355 Thiamine deficiency has been reported to promote a proinflammatory response in Th1  
356 and Th17 cells<sup>57</sup>. To examine the role of thiamine in treating inflammation, *in vitro* testing was  
357 used to mechanistically examine the clinical outcomes. Our *in vitro* model showed that  
358 thiamine could effectively lower IL-17 and increase IL-22 mRNA expression in macrophages.  
359 Both our clinical data, and the *in vitro* studies suggest that thiamine could play a potential role  
360 in attenuating the cytokine storm in patients who have a strong proinflammatory response.

361 A study using a mouse model showed that IL-17 augments respiratory syncytial virus  
362 (RSV)-induced lung inflammation<sup>58</sup>. In that study, immunodepletion of IL-17 before viral  
363 infection resulted in diminished RSV-driven mucous cell hyperplasia and airspace enlargement,  
364 suggesting IL-17 as a potential therapeutic target. Proinflammatory IL-17 production could also  
365 initiate pulmonary eosinophilic response, by promoting proliferation of eosinophils in the bone

366 marrow, followed by recruitment and extravasation into the lungs<sup>59</sup>. These recent findings  
367 suggest that suppression of IL-17 may be vital to managing viral infections, including COVID-19  
368 and their harmful consequences.

369 We derived an effective dose range of thiamine that could be administered for  
370 alleviating the Th17 cell proinflammatory response by using the IL-17 concentrations that we  
371 obtained from our AUD patients (termed as DC), levels found in the literature, and levels in the  
372 healthy control (HV) group. Thiamine has been administered as a treatment in other viral  
373 infections<sup>60,61</sup>, and has proven effective for some inflammatory conditions and symptoms<sup>62,63</sup>.  
374 A well-structured treatment profile of thiamine based on the results of proof of concept *in vitro*  
375 experiments, and analyses of proinflammatory response-relevant disease conditions support  
376 the potential efficacy of thiamine in ameliorating the proinflammatory Th17 response in severe  
377 COVID-19 patients. Use of preventive as well as interventional dosages show potential in the  
378 management of COVID-19. Thiamine  $C_{\text{trough}}$  is reached generally in 10-12 hours; thus, the total  
379 dose prescribed can be divided into two doses per day. This may lead to fewer AEs or other side  
380 effects.

381 One recent report identified that 36.4% of the COVID-19 diagnosed patients have  
382 neurologic symptoms, and this proportion was higher (45.5%) among those COVID-19 patients  
383 with more severe symptoms<sup>51</sup>. Patients with other viral diseases have also shown clinical  
384 symptoms of beriberi<sup>64</sup>, or Wernicke-Korsakoff syndrome (autopsies of 380 people with AIDS  
385 showed Wernicke's encephalopathy in 10% of the cases)<sup>65</sup>, and these conditions are associated  
386 with thiamine deficiency. It is possible that patients with viral infection could have an increased  
387 risk of thiamine deficiency, but this information has remained largely unexplained in viral

388 diseases<sup>66</sup>, including COVID-19. A potential reason could be that a deficiency in thiamine could  
389 be related to the thiamine transport protein, which can have a general preference for multiple  
390 membrane transport molecules which can function as receptors for candidate viruses<sup>67</sup>. The  
391 Th17 proinflammatory response has also been reported in the experimental encephalomyelitis  
392 model<sup>57</sup>. Thus, thiamine could be a therapeutic agent to alleviate neurological symptoms of  
393 COVID-19.

394 Adverse effects (AE) of thiamine are minimal and generally mild. Possible AEs include  
395 nausea, diarrhea, and abdominal pain. Rarely, individuals also suffer serious allergic reactions.  
396 There is no reported drug related symptoms at the 200 mg thiamine dose used in our study,  
397 and there are no reported AEs. A landmark pharmacokinetic study utilizing a 1500 mg  
398 maximum oral dose of thiamine in healthy subjects showed rapid absorption<sup>32</sup>. Moreover,  
399 4000 mg thiamine administration showed no to mild AEs when used in children (Leigh's  
400 disease). Thus, higher doses of thiamine for treatment of COVID-19's cytokine storm could be  
401 considered a safe therapy.

402 Our study has several limitations. This is a small study. However, both clinical and *in*  
403 *vitro* evidence collectively support the potential of thiamine as a therapeutic agent in  
404 attenuating the Th17 proinflammatory response. We did not test the *in vitro/in vivo* efficacy of  
405 thiamine in the treatment of COVID-19 or its derivative stimulated Th17 proinflammatory  
406 response directly. We anticipate conducting such *in vitro* experiments for COVID-19 as a  
407 continuation of this project. Moreover, plasma thiamine levels have not been assessed in  
408 COVID-19. Our study did not have sufficiently large numbers of males and females; thus,  
409 identifying sex-differences was not within the scope of this study.

410 In summary, Thiamine has been approved by the Food and Drug Administration (FDA) of  
 411 the USA as a prescription product and is considered very safe even at higher doses since it is  
 412 water soluble and can be excreted via urine, if in excess<sup>68</sup>. Given its robust safety record, we  
 413 suggest that thiamine should be considered for COVID-19 treatment studies.

414

415 **Tables**

416 Table 1. Neurological symptoms in COVID-19, Viral Encephalitis (Grouped/assorted by the  
 417 neurological spectrum observed in COVID-19), showing their proximity in presentation.  
 418 Therapeutic effects of thiamine on the corresponding neurological symptoms of pro-  
 419 inflammatory origin that are also observed in viral infection.

Neurological symptoms			Corresponding Clinical Indications
COVID-19	Viral Encephalitis	Therapeutic Effects of Thiamine on WKS and other Neurological Conditions	
Central Nervous System (CNS) Symptoms			
Altered Mental Status <sup>51,69</sup>	Disorientation <sup>70</sup>	Mental Confusion <sup>71,72</sup> , Impaired Memory <sup>71</sup> ,	Confusion: WKS Classic Triad
Epiphora, Conjunctival Congestion, or Chemosis (swollen conjunctiva) <sup>73</sup> ; Ophthalmoplegia <sup>74</sup> (part of MFS)	Ocular Paralysis <sup>75</sup> , internuclear Ophthalmoplegia <sup>76-78</sup>	Ophthalmoplegia (nystagmus) <sup>71</sup>	Ocular: WKS Classic Triad
Ataxia <sup>51,79</sup> (part of MFS): Movement <sup>74</sup> , and Unstable Walking <sup>69</sup> ,	Ataxia <sup>26,70</sup>	Gait Ataxia <sup>71</sup>	Ataxia: WKS Classic Triad
Fatigue <sup>69</sup> , Dizziness and Languidness <sup>51,69</sup> , Malaise <sup>69</sup> , Headache <sup>51,69</sup>	Weakness and Somnolence <sup>26</sup> , Nausea <sup>80</sup>	Lack of Energy/Fatigue, Drowsiness, Fainting, Sluggishness <sup>71</sup> ; Apathy <sup>71</sup>	Generalized features
Cerebral Hemorrhage <sup>69</sup> , Cerebral Infarction <sup>69</sup>	Cerebral Hemorrhage <sup>81</sup> , Intracranial Pressure <sup>82</sup>	Hemorrhages <sup>71</sup>	Cerebrovascular

Epilepsy <sup>51,83</sup>	Epilepsy <sup>84,85</sup>	Seizures (Alcohol Withdrawal) <sup>86</sup>	Pathophysiological
Encephalomyelitis: Demyelinating <sup>69,87</sup> , Disseminated <sup>88</sup>	Encephalomyelitis <sup>89,90</sup>	Demyelination <sup>91</sup> within Periventricular Structures	Pathomorphological
Peripheral Nervous System (PNS) Symptoms			
Hypogeusia (low ability to taste) <sup>51,92-94</sup>	Hypogeusia (low ability to taste) <sup>95</sup>	Efficacy Not Well-Established	Sensory
Hyposmia (low ability to smell) <sup>51,93,94,96</sup>	Hyposmia (low ability to smell) <sup>95</sup>	Efficacy Not Well-Established	Sensory
Nerve pain <sup>97</sup> (also in the head and face region <sup>51</sup> )	Neuralgia <sup>98,99</sup>	Neuralgia <sup>100,101</sup>	Neuralgia
Tachycardia <sup>102,103</sup>	Tachycardia <sup>70,104</sup>	Racing of Heart (faster heartbeat), Low Blood pressure <sup>71</sup> , Tachycardia <sup>71</sup>	Cardiovascular
Musculoskeletal Symptoms			
Muscle Injury <sup>51,105</sup> Areflexia (part of MFS) <sup>74</sup>	Dysarthria <sup>26</sup> , Nerve Impairment <sup>106</sup>	Motor impairment <sup>107</sup> , Motor Cortex Excitability <sup>108</sup>	Motor

420 Footnote – WKS: Wernicke Korsakoff Syndrome<sup>109</sup>; MFS: Miller Fisher Syndrome<sup>110</sup>.

421

422 **Figure Legends**

423 Figure 1: Efficacy of thiamine treatment on Th17 cell derived response for IL-17, and IL-22  
 424 cytokines. Levels of IL-17 and IL-22 in healthy volunteers (HV) at baseline; and Disease Controls  
 425 (DC or [alcohol use disorder, AUD]) patients exhibiting a proinflammatory response (n=16) at  
 426 baseline; and anti-inflammatory normalization of cytokines tested after the completion of  
 427 three-week (W3) thiamine treatment. A drop in IL-17 coupled with a mild increase in IL-22 at  
 428 W3 was observed compared to the baseline levels. BL: baseline, W3: three-week of thiamine  
 429 treatment. Data are presented as M±SD. Statistical significance was set as p < 0.05.

430

431 Figure 2: mRNA expression of IL-17 and IL-22 in an *in vitro* model of the mouse macrophage cell  
432 line using a potent proinflammatory agent (alcohol), and preventative administration of  
433 thiamine. Fig. 2a: Significant lowering was observed in IL-17 mRNA expression in “EtOH + V<sub>B1</sub>”  
434 (Bar 4) group compared to the alcohol-treated group (Bar 3). Fig. 2b: Significant elevation was  
435 observed in IL-22 mRNA expression in “EtOH + V<sub>B1</sub>” (Bar 4) group compared to the alcohol-  
436 treated group (Bar 3). Controls (both Fig. 2a and 2b) show normal anti-inflammatory effects of  
437 thiamine on IL-17 and IL-22 response with thiamine administration. Ctrl: Non-treated controls.  
438 V<sub>B1</sub> 0.01 ug/ml. EtOH: alcohol treated. V<sub>B1</sub>+E: thiamine and alcohol treated. Data are presented  
439 as M±SD. Statistical significance was set as  $p < 0.05$ .

440  
441 Figure 3. PRIMARY: A dose titration by disease and proinflammatory Th17 status model of  
442 thiamine administration with parallel representation of Th17 proinflammatory response in  
443 various groups including healthy volunteers and disease groups with pro-inflammatory  
444 response. Fig. 3A: Linear regression model is predictive for the relation between the low dose  
445 thiamine (Vit B1) range versus low IL-17 ranges based on known observed pairs from different  
446 patients; lower range of vit B1 dose (79 mg/daily) corresponding to lower range of IL-17 (15  
447 ng/ml) in the COVID-19 patients. Dark grey shade depicts higher IL-17 response and lighter grey  
448 shade shows lower IL-17 response in various proinflammatory conditions. Fig. 3B: Linear  
449 regression shows the predictive model for the relation between a higher range of Vit B1 dose  
450 versus a higher range of IL-17 levels, derived from the known observed pairs from different  
451 patients; higher range of Vit B1 dose (474 mg/daily) corresponding to higher range of IL-17 (40  
452 ng/ml) reported in COVID-19 patients. High Range Thiamine Dose: Left Y-axis (primary). Low

453 Range Thiamine Dose, Low Range IL-17 levels, and High range IL-17 levels: Right Y-axis

454 (Secondary).

455

456 Figure. 4. Pharmacokinetics parameters of oral thiamine over 10 hr. (Projected) in whole blood

457 and plasma. Fig. 4a: Predicted course of Area Under the Curve (AUC) for low values (79 mg/day)

458 and high values (474 mg/day) of the range of oral thiamine dose in blood and plasma over the

459 10 hours. Fig. 4b: Predicted maximum concentration of low values (79 mg/day) and high values

460 (474 mg/day) of the range of oral thiamine dose in blood and plasma over the first 10 hours.

461 Errors bars show a 5% variability in the pharmacokinetic measures at each dose.

462

## 463 **References**

- 464 1. Hassell JM, Begon M, Ward MJ, Fèvre EM. Urbanization and disease emergence:  
465 dynamics at the wildlife–livestock–human interface. *Trends in ecology & evolution*.  
466 2017;32(1):55-67.
- 467 2. Poon LL, Peiris M. Emergence of a novel human coronavirus threatening human health.  
468 *Nature medicine*. 2020;26(3):317-319.
- 469 3. HuiDS IAE, Madani T, Ntoumi F, Koch R, Dar O. The continuing 2019-nCoV  
470 epidemicthreatof novel coronaviruses to global health: the latest 2019 novel  
471 coronavirus outbreak in Wuhan, China. *Int J Infect Dis*. 2020;91:264-266.
- 472 4. Glass WG, Rosenberg HF, Murphy PM. Chemokine regulation of inflammation during  
473 acute viral infection. *Current opinion in allergy and clinical immunology*. 2003;3(6):467-  
474 473.
- 475 5. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LF. The trinity of COVID-19: immunity,  
476 inflammation and intervention. *Nature Reviews Immunology*. 2020:1-12.
- 477 6. Pedersen SF, Ho Y-C. SARS-CoV-2: a storm is raging. *The Journal of clinical investigation*.  
478 2020;130(5).
- 479 7. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19:  
480 consider cytokine storm syndromes and immunosuppression. *The Lancet*.  
481 2020;395(10229):1033-1034.

- 482 8. Aggarwal S, Gurney AL. IL-17: prototype member of an emerging cytokine family.  
483 *Journal of leukocyte biology*. 2002;71(1):1-8.
- 484 9. Reed M, Morris SH, Owczarczyk AB, Lukacs NW. Deficiency of autophagy protein Map1-  
485 LC3b mediates IL-17-dependent lung pathology during respiratory viral infection via ER  
486 stress-associated IL-1. *Mucosal immunology*. 2015;8(5):1118-1130.
- 487 10. Jain A, Pandey N, Garg R, Kumar R. IL-17 level in patients with Dengue virus infection &  
488 its association with severity of illness. *Journal of clinical immunology*. 2013;33(3):613-  
489 618.
- 490 11. Yuan J, Yu M, Lin Q-W, et al. Neutralization of IL-17 inhibits the production of anti-ANT  
491 autoantibodies in CVB3-induced acute viral myocarditis. *International*  
492 *immunopharmacology*. 2010;10(3):272-276.
- 493 12. Mukherjee S, Lindell DM, Berlin AA, et al. IL-17–induced pulmonary pathogenesis during  
494 respiratory viral infection and exacerbation of allergic disease. *The American journal of*  
495 *pathology*. 2011;179(1):248-258.
- 496 13. Du W-J, Zhen J-H, Zeng Z-Q, et al. Expression of interleukin-17 associated with disease  
497 progression and liver fibrosis with hepatitis B virus infection: IL-17 in HBV infection.  
498 *Diagnostic pathology*. 2013;8(1):40.
- 499 14. Li C, Yang P, Sun Y, et al. IL-17 response mediates acute lung injury induced by the 2009  
500 pandemic influenza A (H1N1) virus. *Cell research*. 2012;22(3):528-538.
- 501 15. Klatt NR, Estes JD, Sun X, et al. Loss of mucosal CD103+ DCs and IL-17+ and IL-22+  
502 lymphocytes is associated with mucosal damage in SIV infection. *Mucosal immunology*.  
503 2012;5(6):646-657.
- 504 16. Ye M, Ren Y, Lv T. Encephalitis as a clinical manifestation of COVID-19. *Brain, behavior,*  
505 *and immunity*. 2020.
- 506 17. Eyerich K, Dimartino V, Cavani A. IL-17 and IL-22 in immunity: Driving protection and  
507 pathology. *European journal of immunology*. 2017;47(4):607-614.
- 508 18. Pacha O, Sallman MA, Evans SE. COVID-19: a case for inhibiting IL-17? *Nature Reviews*  
509 *Immunology*. 2020;20(6):345-346.
- 510 19. Cooper JR, Pincus JH. The role of thiamine in nervous tissue. *Neurochemical research*.  
511 1979;4(2):223-239.
- 512 20. Thornalley PJ. The potential role of thiamine (vitamin B1) in diabetic complications.  
513 *Current diabetes reviews*. 2005;1(3):287-298.
- 514 21. Neri M, Cantatore S, Pomara C, et al. Immunohistochemical expression of  
515 proinflammatory cytokines IL-1 $\beta$ , IL-6, TNF- $\alpha$  and involvement of COX-2, quantitatively  
516 confirmed by Western blot analysis, in Wernicke's encephalopathy. *Pathology-Research*  
517 *and Practice*. 2011;207(10):652-658.
- 518 22. de Andrade JAA, Gayer CRM, de Almeida Nogueira NP, et al. The effect of thiamine  
519 deficiency on inflammation, oxidative stress and cellular migration in an experimental  
520 model of sepsis. *Journal of Inflammation*. 2014;11(1):11.
- 521 23. Menezes RR, Godin AM, Rodrigues FF, et al. Thiamine and riboflavin inhibit production  
522 of cytokines and increase the anti-inflammatory activity of a corticosteroid in a chronic  
523 model of inflammation induced by complete Freund's adjuvant. *Pharmacological*  
524 *Reports*. 2017;69(5):1036-1043.

- 525 24. Shahmiri FA, Soares M, Zhao Y, Sherriff J. High-dose thiamine supplementation improves  
526 glucose tolerance in hyperglycemic individuals: a randomized, double-blind cross-over  
527 trial. *European journal of nutrition*. 2013;52(7):1821-1824.
- 528 25. Protheroe S, Mellor D. Imaging in influenza A encephalitis. *Archives of disease in*  
529 *childhood*. 1991;66(6):702-705.
- 530 26. Brechtelsbauer D, Urbach H, Sommer T, Blümcke I, Woitas R, Solymosi L.  
531 Cytomegalovirus encephalitis and primary cerebral lymphoma mimicking Wernicke's  
532 encephalopathy. *Neuroradiology*. 1997;39(1):19-22.
- 533 27. Thomson AD. Mechanisms of vitamin deficiency in chronic alcohol misusers and the  
534 development of the Wernicke-Korsakoff syndrome. *Alcohol and Alcoholism*.  
535 2000;35(Supplement\_1):2-1.
- 536 28. Vatsalya V, Song M, Schwandt ML, et al. Effects of sex, drinking history, and omega-3  
537 and omega-6 fatty acids dysregulation on the onset of liver injury in very heavy drinking  
538 alcohol-dependent patients. *Alcoholism: Clinical and Experimental Research*.  
539 2016;40(10):2085-2093.
- 540 29. Vatsalya V, Kong M, Cave MC, et al. Association of serum zinc with markers of liver  
541 injury in very heavy drinking alcohol-dependent patients. *The Journal of nutritional*  
542 *biochemistry*. 2018;59:49-55.
- 543 30. Vatsalya V, Agrawal R, Frimodig J, Srivastava S, Schwandt ML. Dysregulation in Plasma  
544  $\omega$ 3 Fatty Acids Concentration and Serum Zinc in Heavy Alcohol-Drinking HCV Patients.  
545 *Advances in Virology*. 2020;2020.
- 546 31. Vatsalya V, Cave MC, Kong M, et al. Keratin 18 is a diagnostic and prognostic factor for  
547 acute alcoholic hepatitis. *Clinical Gastroenterology and Hepatology*. 2019.
- 548 32. Smithline HA, Donnino M, Greenblatt DJ. Pharmacokinetics of high-dose oral thiamine  
549 hydrochloride in healthy subjects. *BMC clinical pharmacology*. 2012;12(1):4.
- 550 33. Mandel H, Berant M, Hazani A, Naveh Y. Thiamine-dependent beriberi in the thiamine-  
551 responsive anemia syndrome. *New England Journal of Medicine*. 1984;311(13):836-838.
- 552 34. Riaz S, Skinner V, Srai SK. Effect of high dose thiamine on the levels of urinary protein  
553 biomarkers in diabetes mellitus type 2. *Journal of pharmaceutical and biomedical*  
554 *analysis*. 2011;54(4):817-825.
- 555 35. Moskowitz A, Andersen LW, Cocchi MN, Karlsson M, Patel PV, Donnino MW. Thiamine  
556 as a Renal Protective Agent in Septic Shock. A Secondary Analysis of a Randomized,  
557 Double-Blind, Placebo-controlled Trial. *Ann Am Thorac Soc*. 2017;14(5):737-741.
- 558 36. Marik PE, Khangoora V, Rivera R, Hooper MH, Catravas J. Hydrocortisone, vitamin C, and  
559 thiamine for the treatment of severe sepsis and septic shock: a retrospective before-  
560 after study. *Chest*. 2017;151(6):1229-1238.
- 561 37. Mouly S. Beri-Beri and thiamine deficiency in HIV infection. *Aids*. 1996;10(8):931.
- 562 38. Arici C, Tebaldi A, Quinzan G, Maggiolo F, Ripamonti D, Suter F. Severe lactic acidosis  
563 and thiamine administration in an HIV-infected patient on HAART. *International journal*  
564 *of STD & AIDS*. 2001;12(6):407-409.
- 565 39. Margolis AM, Heverling H, Pham PA, Stolbach A. A review of the toxicity of HIV  
566 medications. *Journal of Medical Toxicology*. 2014;10(1):26-39.

- 567 40. Di Rocco M, Lamba LD, Minniti G, Caruso U, Naito E. Outcome of thiamine treatment in  
568 a child with Leigh disease due to thiamine-responsive pyruvate dehydrogenase  
569 deficiency. *European Journal of Paediatric Neurology*. 2000;4(3):115-117.
- 570 41. Day E, Bentham PW, Callaghan R, Kuruvilla T, George S. Thiamine for prevention and  
571 treatment of Wernicke-Korsakoff Syndrome in people who abuse alcohol. *Cochrane*  
572 *Database of Systematic Reviews*. 2013(7).
- 573 42. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel  
574 coronavirus in Wuhan, China. *The Lancet*. 2020;395(10223):497-506.
- 575 43. Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: An emerging target of  
576 JAK2 inhibitor Fedratinib. *Journal of Microbiology, Immunology and Infection*. 2020.
- 577 44. Liu Y, Zhang C, Huang F, et al. Elevated plasma level of selective cytokines in COVID-19  
578 patients reflect viral load and lung injury. *National Science Review*. 2020.
- 579 45. Pirowska M, Obtulowicz A, Lipko-Godlewska S, Goździalska A, Podolec K, Wojas-Pelc A.  
580 The level of proinflammatory cytokines: interleukins 12, 23, 17 and tumor necrosis  
581 factor  $\alpha$  in patients with metabolic syndrome accompanying severe psoriasis and  
582 psoriatic arthritis. *Advances in Dermatology and Allergology/Postępy Dermatologii i*  
583 *Alergologii*. 2018;35(4):360.
- 584 46. Kotake S, Udagawa N, Takahashi N, et al. IL-17 in synovial fluids from patients with  
585 rheumatoid arthritis is a potent stimulator of osteoclastogenesis. *The Journal of clinical*  
586 *investigation*. 1999;103(9):1345-1352.
- 587 47. Brunialti MKC, Santos MC, Rigato O, Machado FR, Silva E, Salomao R. Increased  
588 percentages of T helper cells producing IL-17 and monocytes expressing markers of  
589 alternative activation in patients with sepsis. *PloS one*. 2012;7(5):e37393.
- 590 48. Li J, Li M, Su L, et al. Alterations of T helper lymphocyte subpopulations in sepsis, severe  
591 sepsis, and septic shock: a prospective observational study. *Inflammation*.  
592 2015;38(3):995-1002.
- 593 49. Crowe CR, Chen K, Pociask DA, et al. Critical role of IL-17RA in immunopathology of  
594 influenza infection. *The Journal of Immunology*. 2009;183(8):5301-5310.
- 595 50. Qu N, Xu M, Mizoguchi I, et al. Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22,  
596 and IL-23, in inflammatory diseases. *Clinical and Developmental Immunology*.  
597 2013;2013.
- 598 51. Mao L, Wang M, Chen S, et al. Neurological manifestations of hospitalized patients with  
599 COVID-19 in Wuhan, China: a retrospective case series study. 2020.
- 600 52. Hotez PJ, Bottazzi ME, Corry DB. The potential role of TH17 immune responses in  
601 coronavirus immunopathology and vaccine-induced immune enhancement. In: Elsevier;  
602 2020.
- 603 53. Song X, Qian Y. IL-17 family cytokines mediated signaling in the pathogenesis of  
604 inflammatory diseases. *Cell Signal*. 2013;25(12):2335-2347.
- 605 54. Veldhoen M. Interleukin 17 is a chief orchestrator of immunity. *Nat Immunol*.  
606 2017;18(6):612-621.
- 607 55. Lasiglie D, Traggiai E, Federici S, et al. Role of IL-1 Beta in the Development of Human TH  
608 17 Cells: Lesson from NLPR3 Mutated Patients. *PloS one*. 2011;6(5):e20014.
- 609 56. Gu Y, Yang J, Ouyang X, et al. Interleukin 10 suppresses Th17 cytokines secreted by  
610 macrophages and T cells. *European journal of immunology*. 2008;38(7):1807-1813.

- 611 57. Ji Z, Fan Z, Zhang Y, et al. Thiamine deficiency promotes T cell infiltration in experimental  
612 autoimmune encephalomyelitis: the involvement of CCL2. *The Journal of Immunology*.  
613 2014;193(5):2157-2167.
- 614 58. Mebratu YA, Tesfaigzi Y. IL-17 Plays a Role in Respiratory Syncytial Virus-induced Lung  
615 Inflammation and Emphysema in Elastase and LPS-injured Mice. *Am J Respir Cell Mol*  
616 *Biol*. 2018;58(6):717-726.
- 617 59. Murdock BJ, Falkowski NR, Shreiner AB, et al. Interleukin-17 drives pulmonary  
618 eosinophilia following repeated exposure to *Aspergillus fumigatus* conidia. *Infection and*  
619 *immunity*. 2012;80(4):1424-1436.
- 620 60. Shoji S, Furuishi K, Misumi S, Miyazaki T, Kino M, Yamataka K. Thiamine disulfide as a  
621 potent inhibitor of human immunodeficiency virus (type-1) production. *Biochemical and*  
622 *biophysical research communications*. 1994;205(1):967-975.
- 623 61. Butterworth RF, Gaudreau C, Vincelette J, Bourgault A-M, Lamothe F, Nutini A-M.  
624 Thiamine deficiency and Wernicke's encephalopathy in AIDS. *Metabolic brain disease*.  
625 1991;6(4):207-212.
- 626 62. Wallace AE, Weeks WB. Thiamine treatment of chronic hepatitis B infection. *The*  
627 *American journal of gastroenterology*. 2001;96(3):864-868.
- 628 63. Kim W-Y, Jo E-J, Eom JS, et al. Combined vitamin C, hydrocortisone, and thiamine  
629 therapy for patients with severe pneumonia who were admitted to the intensive care  
630 unit: Propensity score-based analysis of a before-after cohort study. *Journal of critical*  
631 *care*. 2018;47:211-218.
- 632 64. Coates PM, Betz JM, Blackman MR, et al. *Encyclopedia of dietary supplements*. CRC  
633 Press; 2010.
- 634 65. Boldorini R, Vago L, Lechi A, Tedeschi F, Trabattoni G. Wernicke's encephalopathy:  
635 occurrence and pathological aspects in a series of 400 AIDS patients. *Acta Bio-medica de*  
636 *L'ateneo Parmense: Organo Della Societa di Medicina e Scienze Naturali di Parma*.  
637 1992;63(1-2):43-49.
- 638 66. Larsen TR, Dragu D, Williams M. Wernicke's encephalopathy: an unusual consequence  
639 of the acquired immune deficiency syndrome—case report and literature review. *Case*  
640 *reports in medicine*. 2013;2013.
- 641 67. Mendoza R, Anderson MM, Overbaugh J. A putative thiamine transport protein is a  
642 receptor for feline leukemia virus subgroup A. *Journal of Virology*. 2006;80(7):3378-  
643 3385.
- 644 68. Plaut G. Water-soluble vitamins, part II (folic acid, riboflavin, thiamine, vitamin B12).  
645 *Annual Review of Biochemistry*. 1961;30(1):409-444.
- 646 69. Wang H-Y, Li X-L, Yan Z-R, Sun X-P, Han J, Zhang B-W. Potential neurological symptoms  
647 of COVID-19. *Therapeutic Advances in Neurological Disorders*.  
648 2020;13:1756286420917830.
- 649 70. Chaudhuri A, Kennedy P. Diagnosis and treatment of viral encephalitis. *Postgraduate*  
650 *medical journal*. 2002;78(924):575-583.
- 651 71. Sechi G, Serra A. Wernicke's encephalopathy: new clinical settings and recent advances  
652 in diagnosis and management. *The Lancet Neurology*. 2007;6(5):442-455.
- 653 72. Reuler JB, Girard DE, Cooney TG. Wernicke's encephalopathy. *New England Journal of*  
654 *Medicine*. 1985;312(16):1035-1039.


- 655 73. Wu P, Duan F, Luo C, et al. Characteristics of ocular findings of patients with coronavirus  
656 disease 2019 (COVID-19) in Hubei Province, China. *JAMA ophthalmology*.  
657 2020;138(5):575-578.
- 658 74. Lantos J, Strauss S, Lin E. COVID-19–Associated Miller Fisher Syndrome: MRI Findings.  
659 *American Journal of Neuroradiology*. 2020.
- 660 75. Keane JR. Bilateral ocular paralysis: analysis of 31 inpatients. *Archives of neurology*.  
661 2007;64(2):178-180.
- 662 76. Keane JR. Internuclear ophthalmoplegia: unusual causes in 114 of 410 patients. *Archives*  
663 *of neurology*. 2005;62(5):714-717.
- 664 77. Hedges III TR. Ophthalmoplegia associated with AIDS. *Survey of ophthalmology*.  
665 1994;39(1):43-51.
- 666 78. Sanjay S, Chan EWe, Gopal L, Hegde SR, Chang BC-M. Complete unilateral  
667 ophthalmoplegia in herpes zoster ophthalmicus. *Journal of Neuro-ophthalmology*.  
668 2009;29(4):325-337.
- 669 79. Yeh EA, Collins A, Cohen ME, Duffner PK, Faden H. Detection of coronavirus in the  
670 central nervous system of a child with acute disseminated encephalomyelitis. *Pediatrics*.  
671 2004;113(1):e73-e76.
- 672 80. Whitley RJ, Gnann JW. Viral encephalitis: familiar infections and emerging pathogens.  
673 *The Lancet*. 2002;359(9305):507-513.
- 674 81. Kabakus N, Gurgoze MK, Yildirim H, Godekmerdan A, Aydin M. Acute hemorrhagic  
675 leukoencephalitis manifesting as intracerebral hemorrhage associated with herpes  
676 simplex virus type I. *Journal of tropical pediatrics*. 2005;51(4):245-249.
- 677 82. Kumar G, Kalita J, Misra UK. Raised intracranial pressure in acute viral encephalitis.  
678 *Clinical neurology and neurosurgery*. 2009;111(5):399-406.
- 679 83. Hao X, Zhou D, Li Z, et al. Severe psychological distress among patients with epilepsy  
680 during the COVID-19 outbreak in southwest China. *Epilepsia*. 2020.
- 681 84. Misra UK, Tan CT, Kalita J. Viral encephalitis and epilepsy. *Epilepsia*. 2008;49:13-18.
- 682 85. AGUILAR MJ, RASMUSSEN T. Role of encephalitis in pathogenesis of epilepsy. *AMA*  
683 *Archives of Neurology*. 1960;2(6):663-676.
- 684 86. Nguyen TA, Lam SW. Phenobarbital and symptom-triggered lorazepam versus  
685 lorazepam alone for severe alcohol withdrawal in the intensive care unit. *Alcohol*.  
686 2020;82:23-27.
- 687 87. Steardo L, Steardo Jr L, Zorec R, Verkhatsky A. Neuroinfection may contribute to  
688 pathophysiology and clinical manifestations of COVID-19. *Acta Physiologica*.  
689 2020:e13473.
- 690 88. Reichard RR, Kashani KB, Boire NA, Constantopoulos E, Guo Y, Lucchinetti CF.  
691 Neuropathology of COVID-19: a spectrum of vascular and acute disseminated  
692 encephalomyelitis (ADEM)-like pathology. *Acta Neuropathologica*. 2020:1-6.
- 693 89. Dale RC. Acute disseminated encephalomyelitis. Paper presented at: Seminars in  
694 pediatric infectious diseases 2003.
- 695 90. Whitley RJ. Viral encephalitis. *New England Journal of Medicine*. 1990;323(4):242-250.
- 696 91. Rao R, Topiwala A. Alcohol use disorders and the brain. *Addiction*. 2020.
- 697 92. Gautier JF, Ravussin Y. A New Symptom of COVID-19: Loss of Taste and Smell. *Obesity*.  
698 2020;28(5):848-848.

- 699 93. Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory dysfunctions  
700 as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-  
701 19): a multicenter European study. *European Archives of Oto-Rhino-Laryngology*.  
702 2020;1-11.
- 703 94. Finsterer J, Stollberger C. Causes of hypogeusia/hyposmia in SARS-CoV2 infected  
704 patients. *Journal of Medical Virology*. 2020.
- 705 95. Henkin R, Larson A, Powell R. Hypogeusia, dysgeusia, hyposmia, and dysosmia following  
706 influenza-like infection. *Annals of Otology, Rhinology & Laryngology*. 1975;84(5):672-  
707 682.
- 708 96. Bénézit F, Le Turnier P, Declerck C, et al. Utility of hyposmia and hypogeusia for the  
709 diagnosis of COVID-19. *The Lancet Infectious Diseases*. 2020.
- 710 97. Azhideh A. COVID-19 Neurological Manifestations. *International Clinical Neuroscience*  
711 *Journal*. 2020;7(2):54.
- 712 98. Tang H, Falcone F, Eljamel S. Herpes simplex encephalitis following microvascular  
713 decompression for trigeminal neuralgia: Case report. *Journal of Neurosurgery*.  
714 2013;118(3):530-533.
- 715 99. Johnson RW, Bouhassira D, Kassianos G, Leplège A, Schmader KE, Weinke T. The impact  
716 of herpes zoster and post-herpetic neuralgia on quality-of-life. *BMC medicine*.  
717 2010;8(1):37.
- 718 100. Rose AS, Jacobson BM. Treatment of trigeminal neuralgia with vitamin B1 (thiamine  
719 hydrochloride). *Archives of Neurology & Psychiatry*. 1940;44(6):1307-1311.
- 720 101. Eckert M, Schejbal P. Therapy of neuropathies with a vitamin B combination.  
721 Symptomatic treatment of painful diseases of the peripheral nervous system with a  
722 combination preparation of thiamine, pyridoxine and cyanocobalamin. *Fortschritte der*  
723 *Medizin*. 1992;110(29):544-548.
- 724 102. He J, Wu B, Chen Y, et al. Characteristic ECG manifestations in patients with COVID-19.  
725 *Canadian Journal of Cardiology*. 2020.
- 726 103. Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C. Cardiac and arrhythmic  
727 complications in patients with COVID-19. *Journal of Cardiovascular Electrophysiology*.  
728 2020;31(5):1003-1008.
- 729 104. Chua KB, Goh KJ, Wong KT, et al. Fatal encephalitis due to Nipah virus among pig-  
730 farmers in Malaysia. *The Lancet*. 1999;354(9186):1257-1259.
- 731 105. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and  
732 treatment coronavirus (COVID-19). In: *Statpearls [internet]*. StatPearls Publishing; 2020.
- 733 106. Ripamonti E, Gaffuri M, Molteni F. Cognitive, neuropsychiatric, and motor profile in post  
734 tick-borne flaviviral encephalomyelitis. *Neurological Sciences*. 2020.
- 735 107. Pitel A-L, Zahr NM, Jackson K, et al. Signs of preclinical Wernicke's encephalopathy and  
736 thiamine levels as predictors of neuropsychological deficits in alcoholism without  
737 Korsakoff's syndrome. *Neuropsychopharmacology*. 2011;36(3):580-588.
- 738 108. Nardone R, Bergmann J, Kronbichler M, et al. Altered motor cortex excitability to  
739 magnetic stimulation in alcohol withdrawal syndrome. *Alcoholism: clinical and*  
740 *experimental research*. 2010;34(4):628-632.


- 741 109. Blass JP, Gibson GE. Abnormality of a thiamine-requiring enzyme in patients with  
742 Wernicke-Korsakoff syndrome. *New England Journal of Medicine*. 1977;297(25):1367-  
743 1370.
- 744 110. Mori M, Kuwabara S, Fukutake T, Yuki N, Hattori T. Clinical features and prognosis of  
745 Miller Fisher syndrome. *Neurology*. 2001;56(8):1104-1106.  
746

# Figure 1

## Fig. 1a



## Fig. 1b



# Figure 2

Fig. 2a






Fig. 2b



# Figure 3


## Primary

### IL-17 Dependent Vit B1 Dose Model




IL-17 Ranges in Different Pro-inflammatory Conditions

#### A: Pred. low Vit B1




#### B: Pred. high Vit B1



# Figure 4

## Fig. 4a



## Fig. 4b

